1. The Possible Cardio protective Effect of Ivabradine versus Bisoprolol on Myocardial Ischemia/Reperfusion Injury in Rats.
- Author
-
Bahy Eldin, Amira Osama, khattab, Monira Ismail, Abdelsameea, Ahmed A., and Elgarhi, Reham I.
- Abstract
Background: Cardiovascular disease is primary cause of death globally, which is primarily caused by coronary artery disease. High resting heart rate is linked to increased cardiovascular and overall death rate, as well as in coronary artery disease and chronic heart failure patients. Decreasing heart rate became a key in the treatment of patients with cardiovascular disease. Our research aimed to evaluate the prophylactic effects of ivabradine on myocardial ischemia reperfusion injury in rats in comparison with bisoprolol. Methods: The study was done on 40 adult male albino rats (10 rats in each group) that were divided into Sham-operated group, control diseased Group, ivabradine-pretreated group and bisoprolol-pretreated group. Blood pressure, heart rate, T wave voltage, biochemical tests and infarct size were measured. Representative cardiac samples of each group were also used for histopathological examination using H&E stain as well as immunohistochemical stain with Bax. Results: Bisoprolol pretreatment reduced the serum level of creatine kinase isoenzyme MB (CK-MB) compared to the control diseased group. Meanwhile, pretreatment with ivabradine produced more decrease in the serum level CK-MB compared to the control diseased group. Oral pretreatment with ivabradine decreased the percentage of the infarct size as compared to control diseased group. In the bisoprolol-pretreated group, the infarct size of the left ventricle was lower than that of control diseased but higher than the ivabradine-pretreated group. Conclusions: It can be concluded from the previous findings that ivabradine possesses protective effect against I/R injury in rats, as evidenced by significant decrease of each of the % of infarct size, T-wave voltage, CK-MB. Thus, ivabradine can be used if bisoprolol is contraindicated. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF